Sales of Flea and Tick Medicines Reach $102 Million

The flea and tick medicine category in Russia continues to grow, though at a significantly slower pace compared to previous years. According to RNC Pharma data, in January to April 2026, sales of ectoparasitic veterinary medicines increased by just 2.6% in physical volume, representing the lowest growth dynamic in the last 4 years. At the same time, the market remains almost entirely divided between manufacturers in Russia and the USA, which together account for 93.6% of sales by value.

In January to April 2026, buyers purchased 13.2 million minimum dosage units of ectoparasitic veterinary medicines, primarily flea and tick remedies. Sales totaled $102 million in retail prices including VAT, according to RNC Pharma data from the Retail Audit of Veterinary Medicines in Russia.Slowest Growth in 4 Years

In physical volume, the market grew by 2.6% compared to January to April 2025. For comparison, growth stood at 3.7% in 2025, while in 2024 demand grew by 7.3% compared to 2023.

In value terms, sales grew by 12.2% compared to January to April 2025. This rate was also the lowest in the last 4 years, as inflationary factors previously had a stronger effect on monetary dynamics.

The slowdown in this category did not begin in 2026. According to RNC Pharma data, the ectoparasitic medicine market reached 18.2 billion rubles in 2025, growing by 17.9% by value. However, physical volume dynamics were noticeably more modest, with 42.3 million minimum dosage units sold over the year, up 3.5% from 2024. Inflation within this group stood at just 2.1%, compared to 13% across the veterinary medicine market as a whole. Against this backdrop, the results for January to April 2026 reflect a gradual category saturation rather than a sharp decline.

According to RNC Pharma estimates, two processes affect the market: active import substitution and the work of foreign manufacturers retaining strong positions in the flea and tick medicine segment.

Medicines Made in Russia Lead in Pack Units

Companies in Russia accounted for 47.9% of the market by value in January to April 2026. Their share grew by 4.4 percentage points over the year. In 2025 as a whole, domestic medicines held a 52.1% share in this category.

In physical volume, manufacturers in Russia remain the market foundation, accounting for 75.5% of sales, or 10 million minimum dosage units. However, compared to January to April 2025, absolute sales of domestic medicines decreased by 0.2%, and their share shrank by 2.1 percentage points. RNC Pharma attributes this to the phase-out of low-cost product lines.

The growing share of flea and tick remedies made in Russia aligns with the overall localization trend in veterinary pharma. In the first half of 2025, the ruble share of domestic veterinary medicines in the retail market exceeded imports for the first time, reaching approximately 53%. One year prior, the figure was 47.9%, and two years prior, 43%. During that same period, 119 domestic manufacturers operated in the market, and companies entering in 2024 had already secured 7% of monetary volume by the first half of 2025.

The ectoparasitic medicine category includes products from 29 companies in Russia, with major sales generated by three manufacturers:

How Digital Traceability Shapes the Veterinary Medicine Market

The veterinary medicine market in Russia is undergoing fundamental changes. Over-the-counter sales of veterinary medicines at unlicensed outlets, previously seen as a gray area, are rapidly becoming easily detectable violations.

Ekoprom holds 18.1% of the market by value. The company sells 8 brands in this segment, with Inspector and RolfClub 3D as key lines.

Vetfarmstandart holds 15.1%. The main product is TixFly.

Agrovetzashchita holds 7.3%. Key lines are Bars and Okvet.

US Brands Maintain Strong Positions

US manufacturers hold second place in total market share. In January to April 2026, they accounted for 45.7% of the market volume in rubles for insectoacaricide medicines. Their share decreased by 3 percentage points compared to January to April 2025, but rose by 5.6 percentage points compared to full-year 2025 results.

US company Zoetis remains the largest single player in the category. Its Simparica brand holds 26.3% of the market. MSD also retains noticeable positions with its Bravecto medicine at 11.9%, despite growing pressure from direct generic alternatives.

Combined, manufacturers in Russia and the USA generate 93.6% of the market in rubles. This structure creates high category concentration: domestic companies dominate in unit volume, while US brands maintain strong positions in monetary terms.

KRKA Significantly Strengthens Position Over Three Years

Among other foreign manufacturers, RNC Pharma highlights Slovenian company KRKA. Over the past three years, the company has grown its presence significantly: in January to April 2026, its market share reached 3.1%, up from no more than 1.2% in 2022. KRKA sells the Fyprist and Ataxa brands in this group.